Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Urokinase-type Plasminogen Activator Receptor,PLAUR/uPAR ELISA kit

Human Urokinase-type Plasminogen Activator Receptor,PLAUR/uPAR ELISA kit

  • 中文名稱：
    人尿激酶型纖溶酶原激活物受體(PLAUR/uPAR)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-E04752h
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3200/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：

    This Human PLAUR ELISA Kit was designed for the quantitative measurement of Human PLAUR protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 0.625 ng/mL-40 ng/mL and the sensitivity is 0.156 ng/mL .

  • 別名：
    CD 87 ELISA Kit; CD87 ELISA Kit; CD87 antigen ELISA Kit; MO 3 ELISA Kit; MO3 ELISA Kit; Monocyte activation antigen Mo3 ELISA Kit; Plasminogen activator receptor urokinase ELISA Kit; Plasminogen activator urokinase receptor ELISA Kit; PLAUR ELISA Kit; U PAR ELISA Kit; u plasminogen activator receptor ELISA Kit; U-PAR ELISA Kit; u-plasminogen activator receptor form 2 ELISA Kit; UPA receptor ELISA Kit; uPAR ELISA Kit; UPAR_HUMAN ELISA Kit; Urinary plasminogen activator receptor ELISA Kit; URKR ELISA Kit; Urokinase plasminogen activator receptor ELISA Kit; Urokinase plasminogen activator surface receptor ELISA Kit; urokinase-type plasminogen activator (uPA) receptor ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測范圍：
    0.625 ng/mL-40 ng/mL
  • 靈敏度：
    0.156 ng/mL
  • 反應(yīng)時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Cancer
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%      
    Three samples of known concentration were tested twenty times on one plate to assess.  
    Inter-assay Precision (Precision between assays): CV%<10%      
    Three samples of known concentration were tested in twenty assays to assess.    
                 
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human uPAR in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)  
    1:1 Average % 90  
    Range % 85-96  
    1:2 Average % 99  
    Range % 92-105  
    1:4 Average % 89  
    Range % 82-98  
    1:8 Average % 95  
    Range % 90-99  
  • 回收率：
    The recovery of human uPAR spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range  
    Serum (n=5) 97 91-104  
    EDTA plasma (n=4) 92 85-98  
                 
                 
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average Corrected  
    10 2.549 2.603 2.576 2.451  
    5 2.058 2.065 2.062 1.937  
    2.5 1.334 1.422 1.378 1.253  
    1.25 0.721 0.714 0.718 0.593  
    0.625 0.461 0.498 0.480 0.355  
    0.312 0.312 0.326 0.319 0.194  
    0.156 0.215 0.226 0.221 0.096  
    0 0.124 0.126 0.125 　  
        　        
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點詳情

  • 功能：
    Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-PA. It is subject to negative-feedback regulation by U-PA which cleaves it into an inactive form.
  • 基因功能參考文獻(xiàn)：
    1. In acutely admitted patients with COPD, elevated PLAUR levels were associated with increased risk of mortality. PMID: 29783959
    2. This study shows that the D2A sequence of the UPAR induces cell growth through alphaVbeta3 integrin and EGFR. PMID: 29184982
    3. High expression of U-PAR is associated with breast cancer. PMID: 29893327
    4. suPAR is associated with the Coronary Artery Calcification score and is a risk factor for new-onset CVD in patients undergoing hemodialysis. PMID: 29734173
    5. Elevated baseline soluble urokinase receptor concentrations independently associate with new-onset microalbuminuria in subjects at increased risk of developing type 2 diabetes. PMID: 28091558
    6. suPAR levels were significantly higher Behcet's disease patients. PMID: 27171829
    7. To develop enzyme-resistant analogues, we applied here the Retro-Inverso (RI) approach, whereby the topology of the side chains is maintained by inverting the sequence of the peptide and the chirality of all residues. Molecular dynamics suggests that peptide RI-3 adopts the turn structure typical of uPAR-FPR1 antagonists PMID: 28465589
    8. results demonstrated that PLAUR induces geftinib-resistance through EGFR/p-AKT/survivin signaling pathway in gefitinib-resistant human lung adenocarcinoma cells. PLAUR could be a novel therapeutic target for gefitinib-resistant NSCLC patients. PMID: 29961070
    9. High Upar expression is associated with breast cancer. PMID: 28498427
    10. Circulating soluble uPAR levels are higher in patients with peripheral arterial disease, particularly in those with extensive atherosclerosis and are predictive of long term cardiovascular and PAD-related outcomes. PMID: 28728756
    11. Data confirmed PLAUR and CDH11, both targets of miR-335, to be overexpressed in gastric cancer tissues. PMID: 29075357
    12. Serum and urine concentration of suPAR did not different between different clinical patterns of nephrotic syndrome in children, regardless the immunosuppressive treatment used. PMID: 29775445
    13. the present study demonstrated that EGF induced aggressiveness of gastric cancer cells by activating epithelial to mesenchymal transition, which involved the activation of the ERK1/2 pathway and, subsequently, uPAR expression PMID: 28849196
    14. The results establish GDE3 as a negative regulator of the uPAR signaling network and, furthermore, highlight GPI-anchor hydrolysis as a cell-intrinsic mechanism to alter cell behavior. PMID: 28849762
    15. uPAR and TF could potentially be attractive targets for molecular imaging and therapy in oral squamous cell carcinoma due to high positive expression rates and tumor-specific expression patterns. High uPAR expression was significantly associated with a reduced survival. PMID: 28841839
    16. suPAR levels are significantly elevated in hemodialysis patients with ESRD and remain associated with adverse outcomes. PMID: 28495863
    17. These findings may show that presenting a high level of suPAR in migraine patients with attack and aura results to predisposition to occurring on the symptoms and that high levels of suPAR, procalcitonin and fibrinogen in patients with migraine result in neurogenic inflammation during migraine headaches. PMID: 28553881
    18. suPAR may be a good novel biomarker for systemic subclinical inflammation and immune activation linked to adolescent obesity. PMID: 28749394
    19. IFN-gamma, CXCL16 and uPAR are promising as effective biomarkers of disease activity, renal damage, and the activity of pathological lesions in systemic lupus erythematosus. PMID: 28628472
    20. Main associations between PLAUR (urokinase plasminogen activator receptor) single nucleotide polymorphisms (SNPs) and markers of airway remodelling, and immunohistochemical analyses PMID: 26869673
    21. Increased uPAR expression was detected in the derma of psoriatic lesions and in the stroma surrounding tumor cells in basal cell carcinomas. PMID: 28429105
    22. Plasma plasminogen activator urokinase receptor (P-suPAR) concentrations are elevated in acute alcohol pancreatitis (AAP) and correlate with the severity of the disease, suggesting P-suPAR may serve as a prognostic marker for AAP severity on admission. PMID: 27841794
    23. We report on the impact of bispecific targeting on the toxicity risks associated with targeting of EGFR and uPAR . Our results show that eBAT is safe and potentially effective at biologically active doses despite EGFR targeting, supporting further translation for patients with sarcomas and other EGFR-expressing malignancies. PMID: 28193671
    24. Improved positron emission tomography imaging of glioblastoma cancer using novel (68)Ga-labeled peptides targeting the urokinase-type plasminogen activator receptor (uPAR). PMID: 28316028
    25. Sera and tissues from malignant mesothelioma (MM) patients showed significantly high plasminogen activator urokinase receptor (uPAR) levels, suggesting the pathogenic role of uPAR in the tumor biology of MM. PMID: 27602956
    26. Levels of circulating cleaved soluble forms plasminogen activator urokinase receptor (DIIDIII-suPAR) in acute myeloid leukemia (AML) patients are higher as compared to controls and significantly decrease after the conditioning. PMID: 27517491
    27. Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication PMID: 27759946
    28. Binding of uPAR to VN triggers integrin-mediated signals, which result in ERK1-2 and RAC activation, accumulation of ROS, and senescence. PMID: 28086938
    29. Plasma levels of intact and cleaved urokinase plasminogen activator receptor do not hold important predictive or prognostic information in men with clinically localised prostate cancer. PMID: 28607123
    30. This study provides novel data that elevated airway and blood uPAR is a feature of asthma and that blood uPAR is particularly related to severe, nonatopic asthma. PMID: 27624865
    31. uPAR and mTORC2 are components of a single cell-signaling pathway. PMID: 27777073
    32. Patients with high suPAR levels were more likely to have progression of their kidney disease. PMID: 28873129
    33. Results provide evidence that uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R. PMID: 27502396
    34. PLAUR to be essential for activation of Checkpoint kinase 1 (CHK1); maintenance of cell cycle arrest after DNA damage in a TP53-dependent manner; expression, nuclear import and recruitment to DNA-damage foci of RAD51 recombinase, the principal protein involved in the homologous recombination repair pathway. PMID: 27685627
    35. The synergy of circulating factor suPAR and APOL1 G1 or G2 on alphavbeta3 integrin activation is a mechanism for CKD. PMID: 28650456
    36. Patients with cancer were significantly older and had a higher burden of comorbidities and previous cancer diagnoses compared to patients who were not diagnosed with cancer. Previous cancer, C-reactive protein (CRP) and suPAR were significantly associated with newly diagnosed cancer during follow-up in multiple logistic regression analyses adjusted for age, sex and CRP PMID: 28393357
    37. This is the first report that PGE2 -induced uPAR expression, which stimulates invasiveness of human gastric cancer AGS cells, is mediated by the EP2 receptor-dependent Src/EGFR/JNK1/2, Erk1/2/AP-1, and Src/EGFR/JNK1/2, Erk1/2/NF-kappaB cascades. PMID: 27377703
    38. Studies indicate the feasibility of combining two U-PA receptor (uPAR)-targeted probes in a preclinical head and neck cancer model. PMID: 28039488
    39. Results suggest that soluble urokinase-type plasminogen activator receptor levels are positively correlated with severity of acute pancreatitis. PMID: 27914940
    40. our study indicates that suPAR increases in patients with AML and this situation is associated with poorer survival. suPAR can thus be used as a diagnostic and prognostic biomarker in AML and may help in the developing of specific therapeutic targets. PMID: 26376588
    41. urokinase plasminogen activator receptor has a role in incidence of venous thromboembolism PMID: 26466866
    42. Our study implies that both soluble UPAR and advanced echocardiography are useful diagnostic tools for identifying patients with diabetes at risk of future clinical heart disease PMID: 26951602
    43. The effect of LIF and uPAR on trophoblast migration and invasion was mediated by PI3K/AKT signaling pathway. PMID: 27133045
    44. findings showed that elevated plasma suPAR levels were independently associated with an increased risk of developing first-time myocardial infarction in an HIV-1-infected population PMID: 26365671
    45. Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker for prognosticating cardiovascular disease PMID: 27052059
    46. we review the human and mouse Ly6/uPAR family gene and protein structure and genomic organization, expression, functions, and evolution, and introduce new names for novel family members PMID: 27098205
    47. Report presence of urokinase-type plasminogen activator receptor in seminal plasma, focusing on its interesting role as reliable and sensitive marker of inflammation for the differential diagnosis of male accessory gland inflammation. PMID: 26384478
    48. uPAR expression is higher in normal pregnant women than that in patients with threatened abortion. uPAR promotes trophoblast migration and invasion during embryo implantation as well as plays a role in trophoblast differentiation into syntrophoblasts. PMID: 26823748
    49. results show that cleaved uPAR forms are significantly increased in patients with advanced prostate cancer. PMID: 26764285
    50. Hypoxia enhanced the endogenous uPAR mRNA and protein expression.HIF-1 protein bound the putative HIF-1 response element on the uPAR promoter.uPAR protein expression was detected in cervical cancer but not in normal cervix or CIN. PMID: 26718775

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cell membrane. Cell projection, invadopodium membrane.; [Isoform 1]: Cell membrane; Lipid-anchor, GPI-anchor.; [Isoform 2]: Secreted.
  • 組織特異性：
    Expressed in neurons of the rolandic area of the brain (at protein level). Expressed in the brain.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 9053

    OMIM: 173391

    KEGG: hsa:5329

    STRING: 9606.ENSP00000339328

    UniGene: Hs.466871